GLP-1 Weight Loss Market "Racing": Eli Lilly's market value exceeds the total number of A-share leading pharmaceutical companies that can invest in expanding into upstream and primary markets. Recently, Peptide Biotech, which is focusing on the GLP-1 target and has made a comprehensive layout in the metabolic disease field, announced the completion of nearly 200 million RMB B+round financing, which is also the second financing completed by Peptide Biotech this year. Under the cold winter of capital, the amount and quantity of investment and financing in the biopharmaceutical market have decreased by nearly 40% year-on-year. Being able to obtain two financing transactions at this time undoubtedly represents the investment institutions' optimism and confidence in the target. Public data shows that the funds raised through this financing will mainly be used for the clinical development of GLP-1 products in Peptide Biology. That is to say, the same type of pipeline product as the "weight loss miracle drug" that has driven the global pharmaceutical market crazy in the past year.